SK7572000A3 - Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans - Google Patents

Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans Download PDF

Info

Publication number: SK7572000A3
Authority: SK; Slovakia
Prior art keywords: carnitine; acetyl; acid; combination; administering
Prior art date: 1997-12-01

Application number

SK757-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Claudio Cavazza

Original Assignee

Sigma Tau Healthscience Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-01

Filing date

1998-11-18

Publication date

2000-11-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26820998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK7572000(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-01 Priority claimed from US08/980,821 external-priority patent/US5863940A/en

1998-11-18 Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa

2000-11-07 Publication of SK7572000A3 publication Critical patent/SK7572000A3/sk

Links

238000000034 method Methods 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 title claims description 20
230000004899 motility Effects 0.000 title claims description 13
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 70
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 57
150000003839 salts Chemical class 0.000 claims abstract description 32
238000011282 treatment Methods 0.000 claims description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 18
241000282412 Homo Species 0.000 claims description 16
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 11
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 9
HNSUOMBUJRUZHJ-UEMBJLSASA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C\C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-UEMBJLSASA-N 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
JATPLOXBFFRHDN-DDWIOCJRSA-N [(2r)-2-acetyloxy-3-carboxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C JATPLOXBFFRHDN-DDWIOCJRSA-N 0.000 claims description 5
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
235000003704 aspartic acid Nutrition 0.000 claims description 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
239000001530 fumaric acid Substances 0.000 claims description 5
239000011976 maleic acid Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 4
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 4
229940095064 tartrate Drugs 0.000 claims description 4
229940066528 trichloroacetate Drugs 0.000 claims description 4
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
229940001468 citrate Drugs 0.000 claims 3
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 3
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims 1
229960001009 acetylcarnitine Drugs 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
206010067162 Asthenospermia Diseases 0.000 abstract 1
208000007799 Asthenozoospermia Diseases 0.000 abstract 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
230000019100 sperm motility Effects 0.000 description 13
229960003604 testosterone Drugs 0.000 description 12
229960004203 carnitine Drugs 0.000 description 9
229940079593 drug Drugs 0.000 description 9
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 8
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 8
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
229940028334 follicle stimulating hormone Drugs 0.000 description 8
210000001550 testis Anatomy 0.000 description 8
102000009151 Luteinizing Hormone Human genes 0.000 description 7
108010073521 Luteinizing Hormone Proteins 0.000 description 7
229940040129 luteinizing hormone Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
102000011022 Chorionic Gonadotropin Human genes 0.000 description 6
108010062540 Chorionic Gonadotropin Proteins 0.000 description 6
210000000918 epididymis Anatomy 0.000 description 6
201000010063 epididymitis Diseases 0.000 description 6
229940084986 human chorionic gonadotropin Drugs 0.000 description 6
239000004480 active ingredient Substances 0.000 description 4
239000003098 androgen Substances 0.000 description 4
206010003883 azoospermia Diseases 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000000047 product Substances 0.000 description 4
230000021595 spermatogenesis Effects 0.000 description 4
229960001603 tamoxifen Drugs 0.000 description 4
230000036541 health Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
208000000509 infertility Diseases 0.000 description 3
230000036512 infertility Effects 0.000 description 3
231100000535 infertility Toxicity 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
ACZKTJZXXSHIGF-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1CCCCCC1(C(=O)O)CO1 ACZKTJZXXSHIGF-UHFFFAOYSA-N 0.000 description 2
206010002261 Androgen deficiency Diseases 0.000 description 2
229940122815 Aromatase inhibitor Drugs 0.000 description 2
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
208000007466 Male Infertility Diseases 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001833 anti-estrogenic effect Effects 0.000 description 2
239000003886 aromatase inhibitor Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960003608 clomifene Drugs 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
239000005516 coenzyme A Substances 0.000 description 2
229940093530 coenzyme a Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
208000021267 infertility disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000036244 malformation Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 2
229960005272 mesterolone Drugs 0.000 description 2
208000008634 oligospermia Diseases 0.000 description 2
230000036616 oligospermia Effects 0.000 description 2
231100000528 oligospermia Toxicity 0.000 description 2
230000008520 organization Effects 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
230000002381 testicular Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
240000001851 Artemisia dracunculus Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000001399 Kallikrein Human genes 0.000 description 1
108060005987 Kallikrein Proteins 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
208000007313 Reproductive Tract Infections Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010043298 Testicular atrophy Diseases 0.000 description 1
HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 description 1
229940100228 acetyl coenzyme a Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000000469 anti-sperm effect Effects 0.000 description 1
201000010788 atrophy of testis Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
230000013439 flagellum movement Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000003794 male germ cell Anatomy 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000006677 mitochondrial metabolism Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
235000021049 nutrient content Nutrition 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
210000004706 scrotum Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
231100000469 sperm hypomotility Toxicity 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
231100001044 testicular atrophy Toxicity 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pregnancy & Childbirth (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK757-2000A 1997-12-01 1998-11-18 Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans SK7572000A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/980,821 US5863940A (en)	1997-12-01	1997-12-01	Medicament and therapeutical method for treating idiopathic asthenozoospermia
US09/122,897 US6090848A (en)	1997-12-01	1998-07-28	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
PCT/IT1998/000324 WO1999027925A1 (fr)	1997-12-01	1998-11-18	Compositions et procedes pour accroitre la concentration et/ou la mobilite des spermatozoides humains

Publications (1)

Publication Number	Publication Date
SK7572000A3 true SK7572000A3 (en)	2000-11-07

Family

ID=26820998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK757-2000A SK7572000A3 (en)	1997-12-01	1998-11-18	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans

Country Status (22)

Country	Link
US (1)	US6090848A (fr)
EP (1)	EP1039894B1 (fr)
JP (1)	JP2001524520A (fr)
KR (1)	KR20010032702A (fr)
CN (1)	CN1184966C (fr)
AT (1)	ATE206916T1 (fr)
AU (1)	AU749754B2 (fr)
BR (1)	BR9814711A (fr)
CA (1)	CA2314942C (fr)
DE (1)	DE69802113T2 (fr)
DK (1)	DK1039894T3 (fr)
EE (1)	EE200000309A (fr)
ES (1)	ES2163896T3 (fr)
HU (1)	HU228989B1 (fr)
IL (1)	IL136299A0 (fr)
IS (1)	IS5501A (fr)
NO (1)	NO20002798L (fr)
PL (1)	PL192438B1 (fr)
PT (1)	PT1039894E (fr)
SK (1)	SK7572000A3 (fr)
TR (1)	TR200001519T2 (fr)
WO (1)	WO1999027925A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2322328T3 (es) *	1999-09-03	2009-06-19	Sigma-Tau Healthscience S.P.A.	L-carnitina ultrafina, procedimientos de preparacion, composiciones que la contienen y procedimiento de uso de la misma.
ITRM20010029A1 (it) *	2001-01-23	2002-07-23	Aldo Fassi	Sali metallici di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per
LV12978B (en) *	2001-09-07	2003-05-20	Ivars Kalvins	Pharmaceutical composition
CN100536912C (zh) *	2001-09-12	2009-09-09	雪兰诺实验室有限公司	人绒毛膜促性腺激素在控制性超排卵中的应用
YU21104A (sh) *	2001-09-12	2006-08-17	Applied Research Systems Ars Holding N.V.	Upotreba hcg i lh u kontrolisanoj hiperstimulaciji ovarijuma
ITRM20010621A1 (it) *	2001-10-18	2003-04-18	Aldo Fassi	Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
RU2215532C2 (ru) *	2001-12-10	2003-11-10	Тихоокеанский научно-исследовательский рыбохозяйственный центр	Способ комплексной переработки внутренностей голотурий с получением биологически активных добавок к пище и биологически активные пищевые добавки "тингол-2" и "эрогол"
ITRM20020194A1 (it) *	2002-04-09	2003-10-09	Sigma Tau Healthscience Spa	Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo.
US7776913B2 (en)	2002-12-13	2010-08-17	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Carnitines for treating or preventing disorders caused by andropause
AT503219B1 (de)	2006-02-03	2008-07-15	Annerl Brigitte	Kombinationspräparat auf basis von antioxidanzien zur verbesserung der samenqualität
ES2524458T3 (es) *	2006-10-18	2014-12-09	Periness Ltd.	DNasa para el tratamiento de la subfertilidad masculina
DE102007053369A1 (de)	2007-11-09	2009-07-02	Alzchem Trostberg Gmbh	Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
WO2009068278A2 (fr) *	2007-11-30	2009-06-04	Bayer Consumer Care Ag	Composition pharmaceutique
US20110015154A1 (en) *	2009-07-20	2011-01-20	Kellermann Gottfried H	Supporting acetylcholine function
US20110098265A1 (en) *	2009-10-28	2011-04-28	Neuroscience, Inc.	Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
BR112016010875B1 (pt) *	2013-12-05	2020-07-14	Alfasigma S.p.A	Composição útil para a promoção da fertilidade feminina
CN105695398A (zh) *	2016-04-25	2016-06-22	广西大学	含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
ES2813573T3 (es) *	2016-07-11	2021-03-24	Laboratoire Des Granions	Composición que comprende L-carnitina para el tratamiento de la infertilidad masculina
CN107375346A (zh) *	2017-07-25	2017-11-24	昭远制药(上海)有限公司	提高人类精子浓度和运动性的组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1235153B (it) *	1988-11-15	1992-06-22	Sigma Tau Ind Farmaceuti	Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) *	1988-12-01	1990-10-24	Sigma Tau Ind Farmaceuti	Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
IT1224842B (it) *	1988-12-27	1990-10-24	Sigma Tau Ind Farmaceuti	Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1240760B (it) *	1990-02-12	1993-12-17	Sigma Tau Ind Farmaceuti	Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
IT1240799B (it) *	1990-03-15	1993-12-17	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche contenenti 3-metiltiopropionil l-carnitina ad attivita' sul sistema cardiovascolare.
IT1244636B (it) *	1991-01-04	1994-08-08	Sigma Tau Ind Farmaceuti	Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1248323B (it) *	1991-05-16	1995-01-05	Sigma Tau Ind Farmaceuti	Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti
IT1245699B (it) *	1991-05-29	1994-10-14	Sigma Tau Ind Farmaceuti	Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1249462B (it) *	1991-10-21	1995-02-23	Sigma Tau Ind Farmaceuti	Impiego di l-carnitina e acil l-carnitine nel trattamento delle oligoastenospermie idiopatiche.
IT1263004B (it) *	1992-10-08	1996-07-23	Sigma Tau Ind Farmaceuti	Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1263013B (it) *	1992-10-20	1996-07-23	Avantgarde Spa	Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
IT1261688B (it) *	1993-05-28	1996-05-29	Avantgarde Spa	Uso di esteri sull'ossidrile della l-carnitina per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT1261696B (it) *	1993-06-02	1996-05-29	Avantgarde Spa	Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT1261984B (it) *	1993-06-22	1996-06-11	Avantgarde Spa	Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT1272290B (it) *	1994-06-20	1997-06-16	Avantgarde Spa	Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee
IT1274156B (it) *	1994-09-08	1997-07-15	Avantgarde Spa	"sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
IT1274157B (it) *	1994-09-08	1997-07-15	Avantgarde Spa	"sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
IT1276225B1 (it) *	1995-10-17	1997-10-27	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US5889055A (en) *	1997-04-04	1999-03-30	Howard; James R.	L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
IT1295408B1 (it) *	1997-10-03	1999-05-12	Sigma Tau Ind Farmaceuti	Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo

1998
- 1998-07-28 US US09/122,897 patent/US6090848A/en not_active Expired - Lifetime
- 1998-11-18 BR BR9814711-0A patent/BR9814711A/pt not_active IP Right Cessation
- 1998-11-18 AU AU12591/99A patent/AU749754B2/en not_active Expired
- 1998-11-18 ES ES98955907T patent/ES2163896T3/es not_active Expired - Lifetime
- 1998-11-18 AT AT98955907T patent/ATE206916T1/de active
- 1998-11-18 CA CA002314942A patent/CA2314942C/fr not_active Expired - Lifetime
- 1998-11-18 IL IL13629998A patent/IL136299A0/xx unknown
- 1998-11-18 CN CNB98813635XA patent/CN1184966C/zh not_active Expired - Lifetime
- 1998-11-18 SK SK757-2000A patent/SK7572000A3/sk unknown
- 1998-11-18 WO PCT/IT1998/000324 patent/WO1999027925A1/fr not_active Application Discontinuation
- 1998-11-18 EP EP98955907A patent/EP1039894B1/fr not_active Expired - Lifetime
- 1998-11-18 TR TR2000/01519T patent/TR200001519T2/xx unknown
- 1998-11-18 HU HU0004562A patent/HU228989B1/hu unknown
- 1998-11-18 KR KR1020007005989A patent/KR20010032702A/ko not_active Ceased
- 1998-11-18 DK DK98955907T patent/DK1039894T3/da active
- 1998-11-18 PL PL342115A patent/PL192438B1/pl unknown
- 1998-11-18 PT PT98955907T patent/PT1039894E/pt unknown
- 1998-11-18 EE EEP200000309A patent/EE200000309A/xx unknown
- 1998-11-18 DE DE69802113T patent/DE69802113T2/de not_active Expired - Lifetime
- 1998-11-18 JP JP2000522911A patent/JP2001524520A/ja active Pending
2000
- 2000-05-19 IS IS5501A patent/IS5501A/is unknown
- 2000-05-31 NO NO20002798A patent/NO20002798L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20002798D0 (no)	2000-05-31
EP1039894B1 (fr)	2001-10-17
TR200001519T2 (tr)	2000-11-21
PT1039894E (pt)	2002-04-29
DE69802113T2 (de)	2002-06-06
IS5501A (is)	2000-05-19
HUP0004562A3 (en)	2003-05-28
ES2163896T3 (es)	2002-02-01
NO20002798L (no)	2000-06-27
HU228989B1 (en)	2013-07-29
BR9814711A (pt)	2000-10-03
US6090848A (en)	2000-07-18
AU749754B2 (en)	2002-07-04
CA2314942A1 (fr)	1999-06-10
PL192438B1 (pl)	2006-10-31
ATE206916T1 (de)	2001-11-15
WO1999027925A1 (fr)	1999-06-10
IL136299A0 (en)	2001-05-20
KR20010032702A (ko)	2001-04-25
PL342115A1 (en)	2001-05-21
DK1039894T3 (da)	2002-02-11
HK1033280A1 (en)	2001-08-24
CN1184966C (zh)	2005-01-19
CA2314942C (fr)	2009-05-05
DE69802113D1 (de)	2001-11-22
HUP0004562A2 (hu)	2001-05-28
JP2001524520A (ja)	2001-12-04
CN1284871A (zh)	2001-02-21
AU1259199A (en)	1999-06-16
EE200000309A (et)	2001-08-15
EP1039894A1 (fr)	2000-10-04

Publication	Publication Date	Title
SK7572000A3 (en)	2000-11-07	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CN1289075C (zh)	2006-12-13	富含反式克罗米酚的克罗米酚组合物的用途
US6235784B1 (en)	2001-05-22	Medicament and therapeutical method for treating idiopathic asthenozoospermia
US8415392B2 (en)	2013-04-09	Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
EP1299105A2 (fr)	2003-04-09	Methode et compositions destines a ameliorer la fertilite masculine et la qualite du sperme
KR20160132500A (ko)	2016-11-18	남성 불임을 치료하기 위한 ｄ－아스파르트산 및 ｌ－아스파르트산 또는 이들 염의 조합체의 용도
EP0662324A1 (fr)	1995-07-12	Utilisation d'agonistes bêta-adrénergiques pour le traitement des pertes de fonction des muscles striés
MXPA00005352A (en)	2001-07-03	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CZ20001999A3 (cs)	2000-12-13	Přípravky a způsoby pro zvyšování koncentrace a/nebo pohyblivosti lidských spermatozoí
CN110917209A (zh)	2020-03-27	含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途
HK1033280B (en)	2005-08-05	Compositions for increasing the concentration and/or motility of spermatozoa in humans
HK1078460B (en)	2008-02-15	Use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine in the manufacture of a combined medicament for the treatment of oligoasthenoteratospermia
CN114306219A (zh)	2022-04-12	稳定的r-氯胺酮药物组合物
ITMI981037A1 (it)	1999-11-13	Uso di l-aspartato di potassio e di magnesio per aumentare la concentrazione ematica di glutammina